Metabolic regulation serves as the master switch governing CD8+ T cell capabilities - their capacity to fight pathogens and cancerous growths, while maintaining immunological memory. When antigen recognition occurs, these immune soldiers transition through immediate metabolic rewiring to fuel their explosive replication and transformation into specialized effector cells or long-lived memory reserves. Yet the precise biochemical pathways directing CD8+ T cell fate determination remain incompletely mapped, like uncharted metabolic circuitry controlling cellular destiny. This incomplete understanding underscores why decoding these metabolic requirements represents the holy grail for designing potent immunotherapeutic strategies that could amplify our body's natural defense mechanisms.
Fig.1 The antitumor-immune response and T-cell fate and function are both influenced by metabolic reprogramming.1,3
At Creative Biolabs, we offer a comprehensive and affordable service for physiological CD8+ T cell metabolic profiling, enabling researchers to investigate how metabolic changes impact CD8+ T cell behavior in various physiological and pathological states, ultimately aiding in the design of targeted immunotherapeutic strategies.
To accurately profile CD8+ T cell metabolism in a physiological context, we employ a comprehensive strategy that begins with ex vivo isolation of primary cells from biological samples, followed by stimulation using physiologically relevant cues like peptide-MHC tetramers and antigen-presenting cells. We then leverage advanced metabolic assays, such as flux cytometry and targeted metabolomics, to quantify key metabolic pathways. To contextualize these findings, we utilize spatial metabolomics and imaging to assess metabolic interactions within the tissue microenvironment and integrate these metabolic profiles with functional assays to correlate metabolism with effector functions. Finally, systems biology approaches are used to integrate multi-omics data, creating robust models that identify critical regulatory nodes and provide a holistic understanding of CD8+ T cell metabolism.
Throughout the whole process, we implement strict quality control and adhere to regulatory development. Combined with the proficiency of our experienced research team, this commitment to excellence enables us to deliver accurate results rapidly and efficiently.
Summary: This study employed a comprehensive metabolomics approach, combining multiple flow injection analysis (FIA) and liquid chromatography (LC) methods with high-resolution mass spectrometry (MS), to meticulously track the metabolic reprogramming of CD8+ T cells during their transition from a naïve to effector state. Analyzing nine time points, the researchers identified significant time-dependent changes in a vast array of metabolic features, particularly within the first 48 hours.
Results: Key findings included the dynamic remodeling of the polyamine biosynthesis pathway and a dramatic shift in phosphatidylcholine acyl chain composition, marked by a depletion of polyunsaturated species, especially those containing 20:4 fatty acid. This extensive dataset, encompassing over 11,000 features, provides a valuable resource for future immunometabolism research.
Fig.2 Key metabolite time courses in the production of polyamines.2,3
In addition, we extend our capabilities to offer specialized services tailored to the unique microenvironment of tumor-infiltrating lymphocytes (TME). This includes detailed characterization of TME CD8+ T cell metabolism, providing insights into the metabolic adaptations within the tumor context. Furthermore, we provide customized assessments, such as precise quantification of amino acid utilization and glucose uptake, allowing for a granular understanding of nutrient dependencies and metabolic vulnerabilities on CD8+ T cell functions.
For inquiries regarding our specialized physiological CD8+ T cell metabolic profiling services, please contact us to discuss your project needs.
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION